Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

Andrés Poveda, Éric Pujade-Lauraine, Michael Friedländer et al.|Journal of Clinical Oncology|2020

Cited by 110